Endo International plc announced that Paladin Labs Inc., an Endo operating company, received Health Canada's approval of XCOPRI(TM) (cenobamate tablets) for adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. Paladin Labs is working collaboratively with the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institute national d'ex excellence en sant et en services sociaux (INESSS) to ensure appropriate patients have access to XCOPRI(TM). Paladin Labs expects to launch XCOPRIâ„¢?

in December 2023. Epilepsy is a chronic neurological condition affecting 300,000 Canadians. It is characterized by recurrent, unprovoked seizures.

While there are many different types of seizures, they can be grouped into two broad categories based on the location of the brain in which the seizure activity starts: generalized seizures and focal seizures. Focal seizures (also called partial-onset seizures) affect 60% of people with epilepsy. While many people with epilepsy will respond to anti-seizure medication, 30% of patients continue to experience seizures despite treatment with currently available medication options.

About XCOPRI(TM), XCOPRI(â„¢? (cenobamate tablets") is indicated as adjunctive therapy in the Management of partial-onset seizures In the US as XCOPRI(R) and Europe under the trademark ONTOZRY(R).